Genetico Medical Center, a subsidiary of the Human Stem Cell Institute, plans to place 12% of its capital during an initial public offering on the Moscow Stock Exchange. The placement date will be announced soon. This IPO should be one of the ten planned this year on the Moscow Stock Exchange.
The Genetic Center for Genetics and Reproductive Medicine announced plans to conduct an IPO (first public offering) on the Moscow Stock Exchange.
Genetico intends to list 12% of its capital, or 10 million shares, on the stock market. The Board of Directors will set the price and placement date in the near future, the company said in a statement.
Genetico plans to use the funds raised during the IPO to develop domestic genetic services, enter foreign markets and create new medicines.
Genetic Medical Center is a resident of Skolkovo and a subsidiary of the Institute of Human Stem Cells. Genetico’s IPO will be the first of ten IPOs planned for 2023 on the Moscow Stock Exchange.
Author:
Kirill Bilyk
Source: RB
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
